Evidence map›Paper›PMID 42690432›Full record

ArticleEuropean journal of trauma and emergency surgery : official publication of the European Trauma Society2026

ABCB5⁺ mesenchymal stem cells enable high-ratio cellular augmentation of bone grafts without loss of osteogenic function.

Jakob Hofmann, Tim Niklas Bewersdorf, Ulrike Sommer, Kai Borcherding, Karsten Thiel, Christoph Ganss, Matthias Gerstner, Markus H Frank, Gerhard Schmidmaier, Mark Andreas Kluth and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of trauma and emergency surgery : official publication of the European Trauma Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jakob HofmannClinic for Trauma and Reconstructive Surgery, Center for Orthopedics, Trauma Surgery and Paraplegiology, University Hospital Heidelberg, Schlierbacher Landstrasse 200a,, 69118, Heidelberg, Germany.
Tim Niklas BewersdorfClinic for Trauma and Reconstructive Surgery, Center for Orthopedics, Trauma Surgery and Paraplegiology, University Hospital Heidelberg, Schlierbacher Landstrasse 200a,, 69118, Heidelberg, Germany.
Ulrike SommerClinic for Trauma and Reconstructive Surgery, Center for Orthopedics, Trauma Surgery and Paraplegiology, University Hospital Heidelberg, Schlierbacher Landstrasse 200a,, 69118, Heidelberg, Germany.
Kai BorcherdingClinic for Trauma and Reconstructive Surgery, Center for Orthopedics, Trauma Surgery and Paraplegiology, University Hospital Heidelberg, Schlierbacher Landstrasse 200a,, 69118, Heidelberg, Germany.
Karsten ThielFraunhofer Institute for Manufacturing Technology and Advanced Materials IFAM, 28359, Bremen, Germany.
Christoph GanssRHEACELL GmbH & Co. KG, 69120, Heidelberg, Germany.
Matthias GerstnerRHEACELL GmbH & Co. KG, 69120, Heidelberg, Germany.
Markus H FrankTransplant Research Program, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA.
Gerhard SchmidmaierClinic for Trauma and Reconstructive Surgery, Center for Orthopedics, Trauma Surgery and Paraplegiology, University Hospital Heidelberg, Schlierbacher Landstrasse 200a,, 69118, Heidelberg, Germany.
Mark Andreas KluthRHEACELL GmbH & Co. KG, 69120, Heidelberg, Germany.
Tobias GrossnerClinic for Trauma and Reconstructive Surgery, Center for Orthopedics, Trauma Surgery and Paraplegiology, University Hospital Heidelberg, Schlierbacher Landstrasse 200a,, 69118, Heidelberg, Germany. tobias.grossner@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous bone grafting remains the standard for reconstruction of bone defects but is constrained by limited graft volume and loss of osteogenic capacity when expanded with acellular materials. We hypothesized that allogeneic ABCB5⁺ mesenchymal stem cells (MSCs) can serve as a biologic cell source to augment bone marrow-derived MSC (BM-MSC) populations without impairing osteogenesis. Primary human BM-MSCs from five donors were combined with GMP-manufactured ABCB5⁺ MSCs at graded replacement ratios (0-95%) and cultured under osteogenic conditions for 21 days. Osteogenic potential was evaluated using complementary assays of mineralization, biochemical activity, and matrix composition. Robust osteogenesis was maintained across all groups, with cultures containing 50% ABCB5⁺ MSCs demonstrating comparable functional osteogenic activity to BM-MSC controls, including similar

Indexed as

ATP Binding Cassette Transporter, Subfamily B, Member 1Bone TransplantationMesenchymal Stem CellsMesenchymal Stem Cell TransplantationOsteogenesisCells, CulturedHumansATP Binding Cassette Transporter, Subfamily B, Member 1

Identifiers

PMID42690432
PMCPMC13541872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.